The content is available as a PDF (1.2 MB).
References
1. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT Working Party. Blood. 2000;95:1931–34.
2. Ball SE. The modern management of severe aplastic anaemia. Br J Haematol. 2000;110:41–53. doi: 10.1046/j.1365-2141.2000.02081.x.
3. Brodsky RA, Jones RJ. Aplastic anaemia. Lancet. 2005;365:1647–56. doi: 10.1016/S0140-6736(05)66515-4.
4. Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol. 2007;136:549–64. doi: 10.1111/j.1365-2141.2006.06461.x.
5. Geroges GE, Storb R. Stem cell transplantation for aplastic anemia. Int J Hematol. 2002;75:141–6. doi: 10.1007/BF02982018.
6. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporin, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96:2049–54.
7. Marsh JCW, Ball SE, Darbyshire P, British Committee for Standards in Hematology (BCSH) et al. Guidelines for the diagnosis and management of acquired aplastic anemia. Br J Haematol. 2003;123:782–90. doi: 10.1046/j.1365-2141.2003.04721.x.
8. Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med. 2005;352:1413–24. doi: 10.1056/NEJMoa042980.
9. Young NS. Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes. Int J Hematol. 2002;75:129–40. doi: 10.1007/BF02982017.
1. http://www.aamds.org/ AA and MDS Foundation
2. http://www.fanconi.org/ Fanconi Anemia Research Fund
1. Berliner N, Horwitz M, Loughran TP Jr. Congenital and acquired neutropenia. Hematology (ASH Educ Program) 2004:63–79
2. Boxer LA, Newburger PE. A molecular classification of congenital neutropenia syndromes. Pediatr Blood Cancer. 2007;49:609–14. doi: 10.1002/pbc.21282.
3. Lakshman R, Finn A. Neutrophil disorders and their management. J Clin Pathol. 2001;54:7–19. doi: 10.1136/jcp.54.1.7.
4. Manny N, Zelig O. Laboratory diagnosis of autoimmune cytopenias. Curr Opin Hematol. 2000;7:414–9. doi: 10.1097/00062752-200011000-00016.
5. Palmblad JE, von dem Borne AE. Idiopathic, immune, infectious and idiosyncratic neutropenias. Semin Hematol. 2002;39:113–20. doi: 10.1053/shem.2002.31919.
6. Welte G, Zeidler C, Dole DC. Severe congenital neutropenia. Semin Hematol. 2006;43:189–95. doi: 10.1053/j.seminhematol.2006.04.004.
1. http://www.rarediseases.org/ NORD, Rare Disorders
2. http://www.nlm.nih.gov/medlineplus/ency/article/001295.htm Medline Plus article
3. http://www.mascc.org MASCC, Supportive Care
4. http://www.neutropenia.ca/ Neutropenia Support Assoc
5. http://www.emedicine.com/med/topic82.htm E-medicine
6. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357:580–7. doi: 10.1056/NEJMra066469.
7. Bolton-Maggs PHB, Chalmers EA, Collins PW, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol. 2006;135:603–33. doi: 10.1111/j.1365-2141.2006.06343.x.
8. Cines DB, Bussel JB, McMillan RB et al. Congenital and acquired thrombocytopenia. Hematology (ASH Educ Program) 2004:390–406
9. Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J Haematol. 2006;134:453–66. doi: 10.1111/j.1365-2141.2006.06215.x.
10. Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood. 2004;103:390–8. doi: 10.1182/blood-2003-05-1742.
11. Geddis AE, Kaushansky K. Inherited thrombocytopenias: toward a molecular understanding of disorders of platelet production. Curr Opin Pediatr. 2004;16:15–22. doi: 10.1097/00008480-200402000-00005.
12. George JN. Platelets. Lancet. 2000;355:1531–9. doi: 10.1016/S0140-6736(00)02175-9.
13. Jelic S, Radulovic S. Chemotherapy-associated thrombocytopenia. Ann J Cancer. 2006;5:371–82. doi: 10.2165/00024669-200605060-00004.
1. http://www.pdsa.org Platelet Disorder Support Assoc
2. http://www.med.unc.edu/isth/ ISTH, Intl Soc Thromb Hemostasis
3. http://www.nlm.nih.gov/medlineplus/ency/ article/000586.htm MedlinePlus
4. http://www.emedicine.com/med/topic3480.htm E-medicine
5. http://marrowfailure.cancer.gov/AMEGA.html NCI, Marrow Failure Disorders
6. Andemariam B, Bussel J. New therapies for ITP. Curr Opin Hematol. 2007;14:427–31. doi: 10.1097/MOH.0b013e3282a4a68b.
7. British Committee for Standards in Hematology (BCSH) Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and pregnancy. Br J Haematol. 2003;120:574–96. doi: 10.1046/j.1365-2141.2003.04131.x.
8. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672–81. doi: 10.1056/NEJMoa054626.
9. Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med. 2005;56:425–42. doi: 10.1146/annurev.med.56.082103.104644.
10. George JN, Woolf SH, Raskob GE. Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of Hematology. Ann Med. 1998;30:38–44. doi: 10.3109/07853899808999383.
11. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004;104:956–60. doi: 10.1182/blood-2003-11-3908.
12. Portielle JEA, Westendorp RGJ, Kluin-Nelemans, et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97:2549–54. doi: 10.1182/blood.V97.9.2549.
13. Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med. 1995;98:436–42. doi: 10.1016/S0002-9343(99)80342-8.
1. http://www.pdsa.org/ PDSA
2. http://www.emedicine.com/EMERG/topic282.htm E-medicine
3. http://www.emedicine.com/med/topic1151.htm E-medicine
4. http://www.scripps.edu/itp/ Scripps Clinic
5. http://www.itpsupport.org.uk ITP Support Assoc
1. Alving BM. How I treat heparin-induced thrombopenia and thrombosis. Blood. 2003;101:31–7. doi: 10.1182/blood-2002-04-1089.
2. Arepally GM, Ortel TL. Hepanin-induced thrombocytopenia. N Engl J Med. 2006;355:809–17. doi: 10.1056/NEJMcp052967.
3. Keeling D, Davidson S, Watson H., British Committee for Standards in Haematology The management of heparin-induced thrombocytopenia. Br J Haematol. 2006;133:259–69. doi: 10.1111/j.1365-2141.2006.06018.x.
4. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood. 2000;96:182–7.
5. Rice L, Attisha WK, Drexler A, et al. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med. 2002;136:210–5. doi: 10.7326/0003-4819-136-3-200202050-00009.
1. http://www.med.unc.edu/isth/welcome Intl Soc Thrombosis Hemostasis
2. http://www.tigc.org/eguidelines/hit05.htm TIGC, Guidelines
1. Allford SL, Hunt BJ, Rose P, British Committee for Standards in Haematology et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic purpura. Br J Haematol. 2003;120:556–73. doi: 10.1046/j.1365-2141.2003.04049.x.
2. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354:1927–35. doi: 10.1056/NEJMcp053024.
3. Ho VT, Cutler C, Carter S, et al. Blood and Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:571–5. doi: 10.1016/j.bbmt.2005.06.001.
4. Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood. 2005;106:11–17. doi: 10.1182/blood-2004-10-4097.
5. Plaimauer B, Zimmermann K, Volkel D, et al. Cloning, expression and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13) Blood. 2002;100:3626–32. doi: 10.1182/blood-2002-05-1397.
6. Richards A, Goodship JA, Goodship THJ. The genetics and pathogenesis of HUS and TTP. Curr Opin Nephrol Hypertens. 2002;11:431–5. doi: 10.1097/00041552-200207000-00010.
7. Sadler JE, Moake JL, Miyata T et al. Recent advances in thrombotic thrombocytopenic purpura. Hematology (ASH Educ Program) 2004:407–23
8. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uremic syndrome. Lancet. 2005;365:1073–86. doi: 10.1056/NEJMcp053024.
1. http://moon.ouhsc.edu/jgeorge/TTP.html TTP-HUS Registry
2. http://www.emedicine.com/emerg/topic579.htm TTP, E-medicine
3. http://www.emedicine.com/emerg/topic238.htm HUS, E-medicine
4. http://www.psbc.org/bulletins/bulletin_v7_n2.pdf Puget Sound Blood Center
5. http://www.crttp.org/ TTP Foundation
6. http://www.nlm.nih.gov/medlineplus/ency/article/000552.htm MedlinePlus
7. http://www.nlm.nih.gov/medlineplus/ency/article/000510.htm MedlinePlus
1. Birgegard G, Aapro MS, Bokemeyer C, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology. 2005;68(suppl 1):3–11. doi: 10.1159/000083128.
2. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004;40:2201–16. doi: 10.1016/j.ejca.2004.07.015.
3. British Committee for Standards in Hematology (BCSH) Guidelines for the clinical use of red cell transfusion. Br J Haematol. 2001;113:24–31. doi: 10.1046/j.1365-2141.2001.02701.x.
4. Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol. 2001;28(suppl 8):49–53. doi: 10.1016/S0093-7754(01)90213-1.
5. Provan D, Weatherall D. Red cells I: inherited anaemias. Lancet. 2000;355:1169–75. doi: 10.1016/S0140-6736(00)02099-7.
6. Provan D, Weatherall D. Red cells II: acquired anemias and polycythaemia. Lancet. 2000;355:1260–8. doi: 10.1016/S0140-6736(00)02099-7.
7. Rizzo JD, Somerfield MP, Hagerty KL, et al. ASH/ASCO 2007 clinical practice guideline update on the use of epoetin and darbepoetin. Blood. 2007;111:x–y. doi: 10.1182/blood-2007-08-109488.
1. http://www.anemiainstitute.org/ Anemia Institute
2. http://www.guideline.gov/ Guideline Clearinghouse
3. http://www.nlm.nih.gov/medlineplus/anemia.html MedlinePlus
4. http://www.anemia.org Anemia Action Council
1. Donovan A, Andrews NC. The molecular regulation of iron metabolism. Hematol J. 2004;5:373–80. doi: 10.1038/sj.thj.6200540.
2. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood. 2000;96:823–33. doi: 10.1016/S0140-6736(00)02099-7.
3. Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol. 2001;28(2 suppl 8):49–53. doi: 10.1016/S0093-7754(01)90213-1.
4. Means RT. Advances in the anemia of chronic disease. Int J Hematol. 1999;70:7–12.
5. Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol. 2005;11:14–23. doi: 10.1532/LH96.04049.
6. Umbreit J. Iron deficiency. Am J Hematol. 2005;78:435–43. doi: 10.1002/ajh.20249.
7. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011–23. doi: 10.1056/NEJMra041809.
8. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet. 2007;370:511–20. doi: 10.1016/S0140-6736(07)61235-5.
1. http://www.nlm.nih.gov/medlineplus/ency/article/000565.htm Medline Plus
2. http://www.nlm.nih.gov/medlineplus/ency/article/000584.htm Medline Plus
3. http://www.umm.edu/blood/aneiron.htm Univ Maryland
4. http://www.emedicine.com/med/topic1188.htm E-medicine
1. Dharmarajan TS, Norkus EP. Approaches to vitamin B12 deficiency. Early treatment may prevent devastating complications. Postgrad Med. 2001;110:99–105. doi: 10.3810/pgm.2001.07.977.
2. Fenech M. The role of folic acid and vitamin B12 in genomic stability of human cells. Mutat Res. 2001;475:57–67. doi: 10.1056/NEJMra041809.
3. Provan D, Weatherall D. Red cells II: acquired anaemias and polycythaemia. Lancet. 2000;355:1260–8. doi: 10.1016/S0140-6736(00)02099-7.
4. Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med. 1997;337:1441–8. doi: 10.1056/NEJM199711133372007.
5. Wickramashinghe SN. The wide spectrum and unresolved issues of megaloblastic anemia. Semin Hematol. 1999;36:3–18.
6. Zittoun J, Zittoun R. Modern clinical testing strategies in cobalamin and folate deficiency. Semin Hematol. 1999;36:35–46.
1. http://www.nlm.nih.gov/medlineplus/ency/article/000567.htm Medline Plus
2. http://web.indstate.edu/thcme/mwking/vitamins.html Introduction to Vitamins
3. http://www.umm.edu/blood/aneper.htm Univ Maryland
4. http://www.emedicine.com/MED/topic1420.htm E-medicine
5. http://www.ashimagebank.org ASH Image Bank
6. Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol. 2007;138:291–304. doi: 10.1111/j.1365-2141.2007.06654.x.
7. British Committee for Standards in Haematology Guidelines for the diagnosis and management of hereditary spherocytosis. Br J Haematol. 2004;126:455–74. doi: 10.1111/j.1365-2141.2004.05052.x.
8. Gallagher PG. Hereditary elliptocytosis: spectrin and protein 4.1R. Semin Hematol. 2004;41:142–64. doi: 10.1053/j.seminhematol.2004.01.003.
9. Gertz A. Management of cold haemolytic syndrome. Br J Haematol. 2007;138:422–9. doi: 10.1111/j.1365-2141.2007.06664.x.
10. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in PNH. N Engl J Med. 2006;355:1233–43. doi: 10.1056/NEJMoa061648.
11. King KE, Ness PM. Treatment of autoimmune hemolytic anemia. Semin Hematol. 2005;42:131–6. doi: 10.1053/j.seminhematol.2005.04.003.
12. Mehta A, Mason PJ, Vulliamy TJ. Glucose-6-phosphate dehydrogenase deficiency. Baillieres Best Pract Res Clin Haematol. 2000;13:21–38. doi: 10.1053/beha.1999.0055.
13. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004;364:1343–60. doi: 10.1016/S0140-6736(04)17192-4.
1. http://www.nlm.nih.gov/medlineplus/ency/article/000571.htm Medline Plus
2. http://www.nlm.nih.gov/medlineplus/ency/article/000534.htm Medline Plus
3. http://www.umm.edu/blood/anehemol.htm Univ Maryland
4. http://www.fpnotebook.com/HEM50.htm Family Practice
5. http://www.emedicine.com/med/topic979.htm E-medicine
1. Eckardt KU. Pathophysiology of renal anemia. Clin Nephrol. 2000;53(1 suppl):S2–8. doi: 10.1111/j.1365-2141.2007.06664.x.
2. Eschbach JW. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI. Semin Nephrol. 2000;20:320–9. doi: 10.1056/NEJMoa061648.
3. MacDougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol. 2000;20:375–81. doi: 10.1053/j.seminhematol.2005.04.003.
4. Ritz E, Schwenger V. The optimal target hemoglobin. Semin Nephrol. 2000;20:382–6.
5. Valderrabano F. Quality of life benefits of early anaemia treatment. Nephrol Dial Transplant. 2000;15(suppl 3):23–8. doi: 10.1016/S0140-6736(04)17192-4.
1. http://www.kidney.org/professionals/doqi/doqi/ doqianemia.html National Kidney Foundation Guidelines
2. http://www.anemiainstitute.org/ Anemia Institute
3. http://www.asn-online.com/ American Society of Nephrology
4. Baglin T, Barrowcliffe TW, Cohen A, et al. Guidelines on the use and monitoring of heparin. Br J Haematol. 2006;133:19–34. doi: 10.1111/j.1365-2141.2005.05953.x.
5. Dahlback B. Blood coagulation. Lancet. 2000;355:1627–32. doi: 10.1016/S0140-6736(00)02225-X.
6. Falanga A. Tumor cell prothrombotic properties. Haemostasis. 2001;31(suppl 1):1–4.
7. Manucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004;104:1243–52. doi: 10.1182/blood-2004-02-0595.
8. Petralia GA, Lemoine NR, Kakkar AK. Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol. 2005;2:356–63. doi: 10.1038/ncponc0225.
1. http://www.med.unc.edu/isth/welcome ISTH
2. http://tollefsen.wustl.edu/projects/coagulation/coagulation.html Washington Univ
3. http://www.indstate.edu/thcme/mwking/blood-coagulation.html Indiana State Univ
4. http://www.nlm.nih.gov/medlineplus/ency/article/001304.htm Medline Plus
1. Dahlback B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med. 2005;257:209–23. doi: 10.1111/j.1365-2796.2004.01444.x.
2. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121:21–35. doi: 10.1046/j.1365-2141.2003.04162.x.
3. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752–63. doi: 10.1056/NEJMra002974.
4. Li T, Chang CY, Jin DY, et al. Identification of the gene for vitamin K epoxide reductase. Nature. 2004;427:541–4. doi: 10.1038/nature02254.
5. Wiestner A, Cho HJ, Asch AS, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 2002;100:3426–8. doi: 10.1182/blood-2002-03-0765.
6. Zeitler H, Ulrich-Merzenich G, Hess L, et al. Treatment of acquired hemophilia by the Bonn-Malmö protocol. Blood. 2005;105:2287–93. doi: 10.1182/blood-2004-05-1811.
1. http://www.med.unc.edu/isth/welcome Intl Soc Thrombosis Hemostasis
2. http://www.ctds.info/vitamink.html Vitamin K Deficiency
3. http://www.emedicine.com/med/topic2385.htm E-Medicine
4. http://www.nlm.nih.gov/medlineplus/ency/ article/002407.htm Medline Plus
1. Berntorp E. Immune tolerance induction: recombinant vs. human-derived product. Haemophilia. 2001;7:109–13. doi: 10.1046/j.1365-2516.2001.00466.x.
2. Bolton-Maggs P, Pasi KJ. Haemophilia A and B. Lancet. 2003;361:1801–9. doi: 10.1016/S0140-6736(03)13405-8.
3. Evatt BL, Farrugia A, Shapiro AD, et al. Haemophilia 2002: emerging risks of treatment. Haemophilia. 2002;8:221–9. doi: 10.1046/j.1365-2516.2002.00612.x.
4. Graw J, Brackmann HH, Oldenburg J, et al. Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet. 2005;6:488–501. doi: 10.1038/nrg1617.
5. Kubisz P, Stasko J. Recombinant activated factor VII in patients at high risk of bleeding. Hematology. 2004;9:317–32. doi: 10.1080/10245330400018581.
6. Srivastava A. Dose and response in haemophilia: optimization of factor replacement therapy. Br J Haematol. 2004;127:12–25. doi: 10.1111/j.1365-2141.2004.05110.x.
7. Van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia. 2003;9:27–31. doi: 10.1046/j.1365-2516.9.s1.10.x.
1. http://www.haemophilia-forum.org Haemophilia Forum
2. http://www.hemophilia.org Natl Hemophilia Foundation
3. http://www.haemophilia.org.uk Haemophilia Society
4. http://www.wfh.org World Fed Hemophilia
5. http://www.nlm.nih.gov/medlineplus/hemophilia.html Medline Plus
6. http://med.unc.edu/isth/welcome International Society of Thrombosis and Hemostasis
1. Berntorp E, Astermark J, Björkman S, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia. 2003;9(suppl 1):1–4. doi: 10.1046/j.1365-2516.9.s1.17.x.
2. Bolton-Maggs P, Pasi KJ. Haemophilia A and B. Lancet. 2003;361:1801–9. doi: 10.1016/S0140-6736(03)13405-8.
3. Di Michele D. Inhibitor development in haemophilia B. Br J Haematol. 2007;138:305–15. doi: 10.1111/j.1365-2141.2007.06657.x.
4. Kubisz P, Stasko J. Recombinant activated factor VII in patients at high risk of bleeding. Hematology. 2004;9:317–32. doi: 10.1080/10245330400018581.
5. Srivastava A. Dose and response in haemophilia: optimization of factor replacement therapy. Br J Haematol. 2004;127:12–25. doi: 10.1111/j.1365-2141.2004.05110.x.
6. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2005;CD003429
7. Van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia. 2003;9:27–31. doi: 10.1046/j.1365-2516.9.s1.10.x.
1. http://www.kcl.ac.uk/ip/petergreen/haemBdatabase.html Hemophilia B Database
2. http://www.haemophilia-forum.org Haemophilia Forum
3. http://www.hemophilia.org Natl Hemophilia Foundation
4. http://www.haemophilia.org.uk Haemophilia Society
5. http://www.wfh.org World Fed Hemophilia
6. http://www.nlm.nih.gov/medlineplus/hemophilia.html Medline Plus
7. http://med.unc.edu/isth/welcome International Society of Thrombosis and Hemostasis
1. Battle J, Noya MS, Giangrande P, et al. Advances in the therapy of von Willebrand disease. Haemophilia. 2002;8:301–7. doi: 10.1046/j.1365-2516.2002.00622.x.
2. Ginsburg D. Molecular genetics of von Willebrand disease. Thromb Haemost. 1999;82:585–91. doi: 10.1111/j.1365-2141.2004.05110.x.
3. Manucci PM. Treatment of von Willebrand’s disease. N Engl J Med. 2004;351:683–94. doi: 10.1056/NEJMra040403.
4. Rodeghiero F, Castaman G. Treatment of von Willebrand disease. Semin Hematol. 2005;42:29–35. doi: 10.1053/j.seminhematol.2004.10.001.
5. Ruggeri ZM. Developing basic and clinical research on von Willebrand factor and von Willebrand disease. Thromb Haemost. 2000;84:147–9.
6. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84:160–74.
7. Schneppenheim R, Budde U. Phenotypic and genotypic diagnosis of von Willebrand disease: a 2004 update. Semin Hematol. 2005;42:15–28. doi: 10.1053/j.seminhematol.2004.10.002.
1. http://www.shef.ac.uk/vwf/ ISTH VWF Database
2. http://www.allaboutbleeding.com/ VWD Resource
3. http://www.nlm.nih.gov/medlineplus/ency/ article/000544.htm VWD, Medline Plus
4. http://www.hemophilia.org/bdi/bdi_types3.htm Hemophilia Foundation
5. www.wfh.org World Fed Hemophilia
6. www.hemophilia.ca/en/2.2.php Canadian Hemophilia Soc
7. www.emedicine.com/med/topic2392.htm E-Medicine
1. Bernard GR, Vincent JH, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709. doi: 10.1056/NEJM200103083441001.
2. De Cicco M. The prothrombotic state in cancer: pathogenetic mechanisms. Crit Rev Hematol Oncol. 2004;50:187–96. doi: 10.1016/j.critrevonc.2003.10.003.
3. Franchini M, Manzato F. Update on the treatment of disseminated intravascular coagulation. Hematology. 2004;9:81–5. doi: 10.1080/1024533042000205504.
4. Levi M. Disseminated intravascular coagulation: what’s new? Crit Care Clin. 2005;21:449–67. doi: 10.1016/j.ccc.2005.02.001.
5. Toh CH, Dennis M. DIC 2002: a review of disseminated intravascular coagulation. Hematology. 2003;8:65–71. doi: 10.1080/1024533031000084213.
6. Warren BL, Reid A, Singer P, et al. High dose antithrombin III in severe sepsis. JAMA. 2001;286:1869–78. doi: 10.1001/jama.286.15.1869.
7. Yanada M, Matsushita T, Suzuki M, et al. DIC in acute leukemia: clinical and laboratory features at presentation. Eur J Haematol. 2006;77:282–7. doi: 10.1111/j.1600-0609.2006.00711.x.
1. http://www.med.unc.edu/isth/ Intl Soc Thromb Haemost
2. http://www.nlm.nih.gov/medlineplus/ency/article/000573.htm Medline Plus
3. http://www.emedicine.com/med/topic577.htm E-medicine
1. Baglin IP, Cousins D, Keeling DM, et al. Recommendations from the British Committee for Standard in Haematology and National Patient Safety Agency. Br J Haematol. 2006;136:26–9. doi: 10.1111/j.1365-2141.2006.06379.x.
2. British Committee for Standards in Haematology (BCSH) Guideline. Investigation and management of heritable thrombophilia. Br J Haematol. 2001;114:512–28. doi: 10.1046/j.1365-2141.2001.02981.x.
3. Francis CW. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl Med. 2007;356:1438–44. doi: 10.1056/NEJMcp067264.
4. Klerk CPW, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23:2130–5. doi: 10.1200/JCO.2005.03.134.
5. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet. 2005;365:1163–74. doi: 10.1016/S0140-6736(05)71880-8.
6. Lee AYY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23:2123–9. doi: 10.1200/JCO.2005.03.133.
7. Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology (ASH Educ Program) 2004;439–56
8. Lyman GH, Khorana AA, Falanga A, et al. ASCO Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25:x–y. doi: 10.1200/JCO.2007.14.1283.
1. http://www.nlm.nih.gov/medlineplus/ency/article/000156.htm Medline Plus
2. http://www.emedicine.com/emerg/topic122.htm E-Medicine
3. http://www.med.unc.edu/isth ISTH
4. http://www.tri-london.ac.uk/ Thrombosis Res Inst
5. http://www.tigc.org TIGC